Ascendis Pharma A/S (ASND) stock
Close on Nov 12, 2026Market cap $16.55BP/E 21.7Yield –
Ascendis Pharma A/S grew revenue 113.4% to €1.05B over the twelve months to Jun 30, 2026. At the latest close the market valued the company at €14.84B, 21.7 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- €14.84B
- P/E ratio
- 21.7
- Price to sales
- 14.17
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- €1.05B
- Net income
- €741.76M
- EPS, diluted
- 11.03 EUR
- Diluted shares
- 68M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $259.28
- Open
- $264.73
- Day's range
- $258.50 – $269.85
- Volume
- 1,281,397
- Average volume (20 days)
- 694,460
- Beta (5 years)
- 0.75
- RSI (14 days)
- 70.2
- Volatility (1 year)
- 38.5%
- Relative volume
- 1.92×
- WACC
- 8.8%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ASND | S&P 500 | Difference | ASND per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +17.7% | -2.7% | +20.3 pts | ||
| 3 months | +4.5% | -1.7% | +6.3 pts | ||
| Year to date | +25.2% | +11.9% | +13.3 pts | ||
| 1 year | +34.1% | +12.0% | +22.1 pts | ||
| 3 years | +195.8% | +78.2% | +117.6 pts | +43.6% | +21.2% |
| 5 years | +71.5% | +73.2% | −1.7 pts | +11.4% | +11.6% |
| 10 years | +1270.3% | +309.6% | +960.6 pts | +29.9% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, EUR
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ascendis Pharma A/S filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Ascendis Pharma A/S
Pharmaceutical Preparations
Ascendis Pharma A/S is a biopharmaceutical company that develops therapies using its proprietary TransCon technology platform to address unmet medical needs. The company focuses primarily on endocrinology rare diseases and oncology, while pursuing partnerships in metabolic diseases, cardiovascular diseases, and ophthalmology. Its commercial portfolio includes YORVIPATH for the treatment of hypoparathyroidism in adults and SKYTROFA for growth hormone deficiency in pediatric and adult patients. Ascendis Pharma provides these prescription medicines to patients and healthcare providers through integrated commercial organizations, specialty pharmacy networks, and regional collaboration partners.
Company profile, executives and historyAscendis Pharma A/S stock: common questions
What is Ascendis Pharma A/S's stock price?
ASND closed at $267.07 on Nov 12, 2026, up 3.00% on the day.
What is Ascendis Pharma A/S's market cap?
Ascendis Pharma A/S was worth $16.55B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ASND's P/E ratio?
ASND trades at 21.7 times earnings, based on diluted earnings per share of 11.03 EUR over the twelve months to Jun 30, 2026.
How much revenue does Ascendis Pharma A/S make?
Ascendis Pharma A/S reported revenue of €1.05B for the twelve months to Jun 30, 2026, up 113.4% from a year earlier.
Does Ascendis Pharma A/S pay a dividend?
No. Ascendis Pharma A/S has not paid a cash dividend over the last twelve months.
When does Ascendis Pharma A/S report earnings next?
Ascendis Pharma A/S's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has ASND stock performed over the past year?
Including dividends, ASND returned +34.1% over the past year, against +12.0% for the S&P 500.
Who are Ascendis Pharma A/S's competitors?
Companies most similar to Ascendis Pharma A/S by business, industry and size include PTCT, BBIO, ANIP, TVTX, IONS.
See a number that looks wrong?